Saxenda - (18 mg/3 mL prefilled syringe Injection)

Generic Name	Liraglutide	**Innovator**	Novo Nordisk
Dosage	18 mg/3 mL prefilled syringe Injection	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: Adult patients with an initial body mass index (BMI) of • 30 kg/m2 or greater (obese), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). Pediatric patients aged 12 years and older with: • body weight above 60 kg and • an initial BMI corresponding to 30 kg/m2 for adults (obese) by international cut-offs.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.